ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 05:23:46 am | |||
| 764 USD | +0.83% |
|
762.2 | -0.23% |
| 14/05 | Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs | RE |
| 14/05 | Argus Adjusts Price Target on Eli Lilly to $840 From $770 | MT |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 34 M€ | +3.53% | - | |
| 25.35% | 129 M€ | +7.05% | - |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.06% | 688B | |
| +31.81% | 588B | |
| -3.42% | 364B | |
| +18.02% | 326B | |
| +4.27% | 285B | |
| +15.26% | 239B | |
| +9.93% | 210B | |
| -7.24% | 200B | |
| +8.12% | 167B | |
| -1.42% | 161B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company